Aquestive Therapeutics (Aquestive Therapeutics) Growth Rank : 5 (As of Apr. 28, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Aquestive Therapeutics Growth Rank?

Aquestive Therapeutics has the Growth Rank of 5.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Aquestive Therapeutics's Growth Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aquestive Therapeutics's Growth Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Aquestive Therapeutics's Growth Rank falls into.

Aquestive Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Aquestive Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Aquestive Therapeutics (Aquestive Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aquestive Therapeutics Inc (NAS:AQST) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Technology Drive, Warren, NJ, USA, 07059

Website

https://www.aquestive.com

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Executives

Carl N Kraus	officer: Chief Medical Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Stephen Wargacki	officer: SVP, Research & Development	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Cassie Jung	officer: SVP, Operations	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Kenneth Truitt	officer: Chief Medical Officer	C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Timothy E Morris	director	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Peter E. Boyd	officer: SVP-Operations/Value Delivery	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Lori J Braender	officer: SVP, General Counsel	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Daniel Barber	officer: SVP-Chief Strategy/Dev Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alexander Mark Schobel	director, officer: Chief Innovation/Tech Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Julie Krop	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Marco Taglietti	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Toth A Ernest Jr	officer: Interim CFO
John T. Maxwell	officer: SVP-Chief Financial Officer	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Keith J Kendall	director, officer: President and CEO	30 TECHNOLOGY DRIVE, WARREN NJ 07059
James S Scibetta	director	C/O BIOENVISION, INC., 345 PARK AVENUE, 41ST. FLOOR, NEW YORK NY 10154